Načítá se...
Drugging PI3K in cancer: refining targets and therapeutic strategies
The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine. The three main classes of PI3K inhibitors currently in...
Uloženo v:
| Vydáno v: | Curr Opin Pharmacol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier Science Ltd
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4728196/ https://ncbi.nlm.nih.gov/pubmed/26117819 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coph.2015.05.016 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|